Verition Fund Management LLC Spring Works Therapeutics, Inc. Transaction History

Verition Fund Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$34.43 - $46.99 $5.32 Million - $7.27 Million	154,624 Added 97.38%	313,408 $14.7 Million
Q1 2025 May 15, 2025	BUY	$32.5 - $59.93 $5.16 Million - $9.52 Million	158,784 New	158,784 $7.01 Million
Q3 2024 Nov 14, 2024	BUY	$32.04 - $42.76 $282,785 - $377,399	8,826 Added 101.75%	17,500 $560,000
Q2 2024 Aug 14, 2024	BUY	$36.06 - $47.62 $312,784 - $413,055	8,674 New	8,674 $326,000
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $147,807 - $290,620	7,804 New	7,804 $284,000

7.39M

23K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.93B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.